1. Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza
- Author
-
John J. Treanor, Frederick G. Hayden, Peter S. Vrooman, Rick Barbarash, Robert Bettis, Dennis Riff, Sudeep Singh, Nelson Kinnersley, Penelope Ward, Roger G. Mills, and null for the US Oral Neuraminidase Study Group
- Subjects
medicine.medical_specialty ,Oseltamivir ,Influenza treatment ,Neuraminidase inhibitor ,business.industry ,medicine.drug_class ,virus diseases ,General Medicine ,Placebo ,medicine.disease ,Laninamivir ,Surgery ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Oseltamivir Phosphate ,Severity of illness ,medicine ,Bronchitis ,business - Abstract
ContextPrevious studies have shown oseltamivir, a neuraminidase inhibitor, to be effective in preventing influenza and treating experimental influenza.ObjectiveTo evaluate the efficacy and safety of oseltamivir in the treatment of naturally acquired influenza infection.DesignRandomized, placebo-controlled, double-blind study conducted January through March 1998.SettingSixty primary care and university health centers throughout the United States.ParticipantsA total of 629 healthy nonimmunized adults aged 18 to 65 years with febrile respiratory illness of no more than 36 hours' duration with temperature of 38°C or more plus at least 1 respiratory symptom and 1 constitutional symptom.InterventionsIndividuals were randomized to 1 of 3 treatment groups with identical appearing pills: oral oseltamivir phosphate, 75 mg twice daily (n = 211) or 150 mg (n = 209) twice daily, or placebo (n = 209).Main Outcome MeasuresDuration and severity of illness in individuals infected with influenza.ResultsTwo individuals withdrew before receiving medication and were excluded from further analyses. A total of 374 individuals (59.6%) were infected with influenza. Their duration of illness was reduced by more than 30% with both oseltamivir, 75 mg twice daily (median, 71.5 hours; P
- Published
- 2000